BIOSPECIMEN SHARED RESOURCE: ABSTRACT The Biospecimen Shared Resource (BSR), led by Andrew K. Godwin, PhD (Founding Director, BSR; Deputy Director, KUCC, and D3ET member), and by Rashna Madan, MBBS, FCAP, FASCP (Assistant Director, BSR), plays a vital role in The University of Kansas Cancer Center (KUCC) by its ethical collection, storage, annotation, and distribution of high-quality human biospecimens, such as fresh/fresh-frozen tumor tissues of varying histology and bodily fluids (e.g., blood, bone marrow, saliva, urine, ascites fluids), which are essential to support translational research and investigator-initiated studies. The BSR also provides expert histopathology support and combines the expertise of pathologists, translational researchers, and technical personnel to produce a comprehensive and focused approach to support the research activities at KUCC. The BSR, rated “exceptional to outstanding” in 2017, continues to evolve to meet the ever-expanding and diverse needs of our KUCC members for highly annotated clinical samples. Additionally, tissue biospecimen collection is facilitated by pathology assistants, residents and fellows at the KU Hospital and the Indian Creek Campus (ICC) as part of The University of Kansas Health System’s (TUKHS) commitment to the BSR. The BSR is fully equipped for biospecimen collection, processing, and distribution, and thus, the BSR adheres to the OSHA laboratory standards for handling cryogens, ISBER Best Practice for Repositories, and NCI Best Practices for Biospecimen Resources, and has developed Standard Operating Procedures to govern each of these processes. The collection, processing, and distribution of specimens by the BSR staff has grown substantially over the funding period and now includes collections of pediatric specimens from ICC and Children’s Mercy (CM) and underserved populations from the satellite biospecimen bank at Truman Medical Center (TMC), a member of the Masonic Cancer Alliance (MCA) and the largest safety-net provider in the Kansas City Metropolitan area. Since founding the CCSG BSR in 2011, we have enrolled 51,916 consented individuals and supported the banking of 4,795 participants for investigator-initiated studies resulting in regular usage of de- identified biospecimens and matching clinical data. During the current grant cycle (2016-2020), the BSR provided key services in support of 150 publications (57 papers ≥ 10 impact factor), 96 unique cancer center members, and >35 NIH/NIGMS/NCI grants and contracts including, 1 K01, 1 R00, 12 R01s, 1 R03, 6 R21s, 1 R33, 1 R35, 2 R43, 2 P20, 1 P30, 1 P41, 2 U01, TCGA 13XS194, & CPTAC 14X215, 16x257, 19x139 and 311 clinical trials. In the reporting year (2020), the BRS supported 82 different users (54 KUCC members across all three programs, of which 85% were funded and 28 non-members, including 16 cancer-focused researchers nationally). The proposed budget of the BSR (year 11) is $1,511,949, yet the CCSG request is $118,342. As such, th...